Endoplasmic reticulum stress associated responses in cancer

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1843, Issue 10, 2014, Pages 2143-2149

  Wang, Wen An ^a   Groenendyk, Jody ^a   Michalak, Marek ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Endoplasmic reticulum stress; Unfolded protein response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; GLUCOSE REGULATED PROTEIN 78; INITIATION FACTOR 2ALPHA; PROTEIN IRE1; PROTEIN IRE1 ALPHA; SIGMA 1 OPIATE RECEPTOR; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL METABOLISM; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; ENVIRONMENTAL STRESS; HUMAN; HYPOXIA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; REVIEW; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

CANCER; ENDOPLASMIC RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE;

ANIMALS; CELL DEATH; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; SIGNAL TRANSDUCTION; UNFOLDED PROTEIN RESPONSE;

EID: 84905019401     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2014.01.012     Document Type: Review

References (110)

1. Stutzmann G.E., Mattson M.P. Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease. Pharmacol. Rev. 2011, 63:700-727.
2. Martinon F. Targeting endoplasmic reticulum signaling pathways in cancer. Acta Oncol. 2012, 51:822-830.
3. Groenendyk J., Agellon L.B., Michalak M. Coping with endoplasmic reticulum stress in the cardiovascular system. Annu. Rev. Physiol. 2013, 75:49-67.
4. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58:1408-1416.
5. Moenner M., Pluquet O., Bouchecareilh M., Chevet E. Integrated endoplasmic reticulum stress responses in cancer. Cancer Res. 2007, 67:10631-10634.
6. Shamu C.E., Walter P. Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. EMBO J. 1996, 15:3028-3039.
7. Harding H.P., Zhang Y., Bertolotti A., Zeng H., Ron D. Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 2000, 5:897-904.
8. Haze K., Yoshida H., Yanagi H., Yura T., Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol. Biol. Cell 1999, 10:3787-3799.
9. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13:89-102.
10. Bertolotti A., Zhang Y., Hendershot L.M., Harding H.P., Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2000, 2:326-332.
11. Okamura K., Kimata Y., Higashio H., Tsuru A., Kohno K. Dissociation of Kar2p/BiP from an ER sensory molecule, Ire1p, triggers the unfolded protein response in yeast. Biochem. Biophys. Res. Commun. 2000, 279:445-450.
12. Shen J., Chen X., Hendershot L., Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev. Cell 2002, 3:99-111.
13. Luo S., Baumeister P., Yang S., Abcouwer S.F., Lee A.S. Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J. Biol. Chem. 2003, 278:37375-37385.
14. Ameri K., Harris A.L. Activating transcription factor 4. Int. J. Biochem. Cell Biol. 2008, 40:14-21.
15. Han D., Lerner A.G., Vande Walle L., Upton J.P., Xu W., Hagen A., Backes B.J., Oakes S.A., Papa F.R. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell 2009, 138:562-575.
16. Hetz C., Glimcher L.H. Fine-tuning of the unfolded protein response: assembling the IRE1alpha interactome. Mol. Cell 2009, 35:551-561.
17. Hollien J., Lin J.H., Li H., Stevens N., Walter P., Weissman J.S. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J. Cell Biol. 2009, 186:323-331.
18. Sidrauski C., Walter P. The transmembrane kinase Ire1p is a site-specific endonuclease that initiates mRNA splicing in the unfolded protein response. Cell 1997, 90:1031-1039.
19. Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell 2001, 107:881-891.
20. Yoshida H., Okada T., Haze K., Yanagi H., Yura T., Negishi M., Mori K. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. Mol. Cell. Biol. 2000, 20:6755-6767.
21. Verfaillie T., Garg A.D., Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. Cancer Lett. 2013, 332:249-264.
22. Kim R., Emi M., Tanabe K., Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006, 11:5-13.
23. Oyadomari S., Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004, 11:381-389.
24. McCullough K.D., Martindale J.L., Klotz L.O., Aw T.Y., Holbrook N.J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 2001, 21:1249-1259.
25. Marciniak S.J., Yun C.Y., Oyadomari S., Novoa I., Zhang Y., Jungreis R., Nagata K., Harding H.P., Ron D. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev. 2004, 18:3066-3077.
26. Nishitoh H., Matsuzawa A., Tobiume K., Saegusa K., Takeda K., Inoue K., Hori S., Kakizuka A., Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002, 16:1345-1355.
27. Urano F., Wang X., Bertolotti A., Zhang Y., Chung P., Harding H.P., Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000, 287:664-666.
28. Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T., Tohyama M. Activation of caspase-12, an endoplastic reticulum (ER) resident caspase, through tumor necrosis factor receptor-associated factor 2-dependent mechanism in response to the ER stress. J. Biol. Chem. 2001, 276:13935-13940.
29. Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B.A., Yuan J. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000, 403:98-103.
30. Fischer H., Koenig U., Eckhart L., Tschachler E. Human caspase 12 has acquired deleterious mutations. Biochem. Biophys. Res. Commun. 2002, 293:722-726.
31. Bian Z.M., Elner S.G., Elner V.M. Regulated expression of caspase-12 gene in human retinal pigment epithelial cells suggests its immunomodulating role. Invest. Ophthalmol. Vis. Sci. 2008, 49:5593-5601.
32. Upton J.P., Wang L., Han D., Wang E.S., Huskey N.E., Lim L., Truitt M., McManus M.T., Ruggero D., Goga A., Papa F.R., Oakes S.A. IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science 2012, 338:818-822.
33. Lerner A.G., Upton J.P., Praveen P.V., Ghosh R., Nakagawa Y., Igbaria A., Shen S., Nguyen V., Backes B.J., Heiman M., Heintz N., Greengard P., Hui S., Tang Q., Trusina A., Oakes S.A., Papa F.R. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 2012, 16:250-264.
34. Bouchecareilh M., Higa A., Fribourg S., Moenner M., Chevet E. Peptides derived from the bifunctional kinase/RNase enzyme IRE1alpha modulate IRE1alpha activity and protect cells from endoplasmic reticulum stress. FASEB J. 2011, 25:3115-3129.
35. Sandow J.J., Dorstyn L., O'Reilly L.A., Tailler M., Kumar S., Strasser A., Ekert P.G. ER stress does not cause upregulation and activation of caspase-2 to initiate apoptosis. Cell Death Differ. 2013, 168. 10.1038/cdd.2013.
36. Park H.R., Tomida A., Sato S., Tsukumo Y., Yun J., Yamori T., Hayakawa Y., Tsuruo T., Shin-ya K. Effect on tumor cells of blocking survival response to glucose deprivation. J. Natl. Cancer Inst. 2004, 96:1300-1310.
37. Tu B.P., Weissman J.S. The FAD- and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. Mol. Cell 2002, 10:983-994.
38. Li J., Lee A.S. Stress induction of GRP78/BiP and its role in cancer. Curr. Mol. Med. 2006, 6:45-54.
39. Schonthal A.H. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem. Pharmacol. 2013, 85:653-666.
40. Bini L., Magi B., Marzocchi B., Arcuri F., Tripodi S., Cintorino M., Sanchez J.C., Frutiger S., Hughes G., Pallini V., Hochstrasser D.F., Tosi P. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997, 18:2832-2841.
41. Fernandez P.M., Tabbara S.O., Jacobs L.K., Manning F.C., Tsangaris T.N., Schwartz A.M., Kennedy K.A., Patierno S.R. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res. Treat. 2000, 59:15-26.
42. Xing X., Lai M., Wang Y., Xu E., Huang Q. Overexpression of glucose-regulated protein 78 in colon cancer. Clin. Chim. Acta 2006, 364:308-315.
43. Fu Y., Li J., Lee A.S. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007, 67:3734-3740.
44. Reddy R.K., Mao C., Baumeister P., Austin R.C., Kaufman R.J., Lee A.S. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J. Biol. Chem. 2003, 278:20915-20924.
45. Wang C., Jiang K., Gao D., Kang X., Sun C., Zhang Q., Li Y., Sun L., Zhang S., Guo K., Liu Y. Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78. PLoS One 2013, 8:e55981.
46. Martin S., Lamb H.K., Brady C., Lefkove B., Bonner M.Y., Thompson P., Lovat P.E., Arbiser J.L., Hawkins A.R., Redfern C.P. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br. J. Cancer 2013, 109:433-443.
47. Suzuki T., Lu J., Zahed M., Kita K., Suzuki N. Reduction of GRP78 expression with siRNA activates unfolded protein response leading to apoptosis in HeLa cells. Arch. Biochem. Biophys. 2007, 468:1-14.
48. Jiang C.C., Chen L.H., Gillespie S., Wang Y.F., Kiejda K.A., Zhang X.D., Hersey P. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res. 2007, 67:9750-9761.
49. Lee E., Nichols P., Spicer D., Groshen S., Yu M.C., Lee A.S. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006, 66:7849-7853.
50. Thornton M., Aslam M.A., Tweedle E.M., Ang C., Campbell F., Jackson R., Costello E., Rooney P.S., Vlatkovic N., Boyd M.T. The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. Int. J. Cancer 2013, 133:1408-1418.
51. Firczuk M., Gabrysiak M., Barankiewicz J., Domagala A., Nowis D., Kujawa M., Jankowska-Steifer E., Wachowska M., Glodkowska-Mrowka E., Korsak B., Winiarska M., Golab J. GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death Dis. 2013, 4:e741.
52. Kang J., Zhao G., Lin T., Tang S., Xu G., Hu S., Bi Q., Guo C., Sun L., Han S., Xu Q., Nie Y., Wang B., Liang S., Ding J., Wu K. A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells. Cancer Lett. 2013, 339:247-259.
53. Koong A.C., Chauhan V., Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol. Ther. 2006, 5:756-759.
54. White-Gilbertson S., Hua Y., Liu B. The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front. Genet. 2013, 4:109.
55. Romero-Ramirez L., Cao H., Nelson D., Hammond E., Lee A.H., Yoshida H., Mori K., Glimcher L.H., Denko N.C., Giaccia A.J., Le Q.T., Koong A.C. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004, 64:5943-5947.
56. Fujimoto T., Onda M., Nagai H., Nagahata T., Ogawa K., Emi M. Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer 2003, 10:301-306.
57. Shuda M., Kondoh N., Imazeki N., Tanaka K., Okada T., Mori K., Hada A., Arai M., Wakatsuki T., Matsubara O., Yamamoto N., Yamamoto M. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J. Hepatol. 2003, 38:605-614.
58. Reimold A.M., Iwakoshi N.N., Manis J., Vallabhajosyula P., Szomolanyi-Tsuda E., Gravallese E.M., Friend D., Grusby M.J., Alt F., Glimcher L.H. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001, 412:300-307.
59. Iwakoshi N.N., Lee A.H., Glimcher L.H. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol. Rev. 2003, 194:29-38.
60. Shaffer A.L., Shapiro-Shelef M., Iwakoshi N.N., Lee A.H., Qian S.B., Zhao H., Yu X., Yang L., Tan B.K., Rosenwald A., Hurt E.M., Petroulakis E., Sonenberg N., Yewdell J.W., Calame K., Glimcher L.H., Staudt L.M. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004, 21:81-93.
61. Carrasco D.R., Sukhdeo K., Protopopova M., Sinha R., Enos M., Carrasco D.E., Zheng M., Mani M., Henderson J., Pinkus G.S., Munshi N., Horner J., Ivanova E.V., Protopopov A., Anderson K.C., Tonon G., DePinho R.A. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 2007, 11:349-360.
62. Thorpe J.A., Schwarze S.R. IRE1alpha controls cyclin A1 expression and promotes cell proliferation through XBP-1. Cell Stress Chaperones 2010, 15:497-508.
63. Hetz C., Bernasconi P., Fisher J., Lee A.H., Bassik M.C., Antonsson B., Brandt G.S., Iwakoshi N.N., Schinzel A., Glimcher L.H., Korsmeyer S.J. Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006, 312:572-576.
64. Rodriguez D.A., Zamorano S., Lisbona F., Rojas-Rivera D., Urra H., Cubillos-Ruiz J.R., Armisen R., Henriquez D.R., Cheng E.H., Letek M., Vaisar T., Irrazabal T., Gonzalez-Billault C., Letai A., Pimentel-Muinos F.X., Kroemer G., Hetz C. BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1alpha. EMBO J. 2012, 31:2322-2335.
65. Hetz C., Chevet E., Harding H.P. Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 2013, 12:703-719.
66. Mimura N., Fulciniti M., Gorgun G., Tai Y.T., Cirstea D., Santo L., Hu Y., Fabre C., Minami J., Ohguchi H., Kiziltepe T., Ikeda H., Kawano Y., French M., Blumenthal M., Tam V., Kertesz N.L., Malyankar U.M., Hokenson M., Pham T., Zeng Q., Patterson J.B., Richardson P.G., Munshi N.C., Anderson K.C. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood 2012, 119:5772-5781.
67. Papandreou I., Denko N.C., Olson M., Van Melckebeke H., Lust S., Tam A., Solow-Cordero D.E., Bouley D.M., Offner F., Niwa M., Koong A.C. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood 2011, 117:1311-1314.
68. Cross B.C., Bond P.J., Sadowski P.G., Jha B.K., Zak J., Goodman J.M., Silverman R.H., Neubert T.A., Baxendale I.R., Ron D., Harding H.P. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E869-E878.
69. Ri M., Tashiro E., Oikawa D., Shinjo S., Tokuda M., Yokouchi Y., Narita T., Masaki A., Ito A., Ding J., Kusumoto S., Ishida T., Komatsu H., Shiotsu Y., Ueda R., Iwawaki T., Imoto M., Iida S. Identification of toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012, 2:e79.
70. Zhang H., Nakajima S., Kato H., Gu L., Yoshitomi T., Nagai K., Shinmori H., Kokubo S., Kitamura M. Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues. Br. J. Pharmacol. 2013, 170:822-834.
71. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr. Mol. Med. 2006, 6:55-69.
72. Koumenis C., Naczki C., Koritzinsky M., Rastani S., Diehl A., Sonenberg N., Koromilas A., Wouters B.G. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol. Cell. Biol. 2002, 22:7405-7416.
73. Bi M., Naczki C., Koritzinsky M., Fels D., Blais J., Hu N., Harding H., Novoa I., Varia M., Raleigh J., Scheuner D., Kaufman R.J., Bell J., Ron D., Wouters B.G., Koumenis C. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005, 24:3470-3481.
74. Blais J.D., Addison C.L., Edge R., Falls T., Zhao H., Wary K., Koumenis C., Harding H.P., Ron D., Holcik M., Bell J.C. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol. Cell. Biol. 2006, 26:9517-9532.
75. Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., Sadri N., Yun C., Popko B., Paules R., Stojdl D.F., Bell J.C., Hettmann T., Leiden J.M., Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol. Cell 2003, 11:619-633.
76. Ameri K., Lewis C.E., Raida M., Sowter H., Hai T., Harris A.L. Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 2004, 103:1876-1882.
77. Ye J., Kumanova M., Hart L.S., Sloane K., Zhang H., De Panis D.N., Bobrovnikova-Marjon E., Diehl J.A., Ron D., Koumenis C. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J. 2010, 29:2082-2096.
78. Horiguchi M., Koyanagi S., Okamoto A., Suzuki S.O., Matsunaga N., Ohdo S. Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors. Cancer Res. 2012, 72:395-401.
79. Rzymski T., Milani M., Pike L., Buffa F., Mellor H.R., Winchester L., Pires I., Hammond E., Ragoussis I., Harris A.L. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 2010, 29:4424-4435.
80. Mujcic H., Nagelkerke A., Rouschop K.M., Chung S., Chaudary N., Span P.N., Clarke B., Milosevic M., Sykes J., Hill R.P., Koritzinsky M., Wouters B. Hypoxic activation of the PERK/eIF2alpha arm of the unfolded protein response promotes metastasis through induction of LAMP3. Clin. Cancer Res. 2013, 10.1158/1078-0432.CCR-13-0526.
81. Nagy P., Varga A., Pircs K., Hegedus K., Juhasz G. Myc-driven overgrowth requires unfolded protein response-mediated induction of autophagy and antioxidant responses in Drosophila melanogaster. PLoS Genet. 2013, 9:e1003664.
82. Dey S., Tameire F., Koumenis C. PERK-ing up autophagy during MYC-induced tumorigenesis. Autophagy 2013, 9:612-614.
83. Cojocari D., Vellanki R.N., Sit B., Uehling D., Koritzinsky M., Wouters B.G. New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1alpha signaling is essential for promoting adaptation and survival to hypoxia. Radiother. Oncol. 2013, 10.1016/j.radonc.2013.06.005.
84. Axten J.M., Medina J.R., Feng Y., Shu A., Romeril S.P., Grant S.W., Li W.H., Heerding D.A., Minthorn E., Mencken T., Atkins C., Liu Q., Rabindran S., Kumar R., Hong X., Goetz A., Stanley T., Taylor J.D., Sigethy S.D., Tomberlin G.H., Hassell A.M., Kahler K.M., Shewchuk L.M., Gampe R.T. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem. 2012, 55:7193-7207.
85. Atkins C., Liu Q., Minthorn E., Zhang S.Y., Figueroa D.J., Moss K., Stanley T.B., Sanders B., Goetz A., Gaul N., Choudhry A.E., Alsaid H., Jucker B.M., Axten J.M., Kumar R. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013, 73:1993-2002.
86. Chen Y.J., Su J.H., Tsao C.Y., Hung C.T., Chao H.H., Lin J.J., Liao M.H., Yang Z.Y., Huang H.H., Tsai F.J., Weng S.H., Wu Y.J. Sinulariolide induced hepatocellular carcinoma apoptosis through activation of mitochondrial-related apoptotic and PERK/eIF2alpha/ATF4/CHOP pathway. Molecules 2013, 18:10146-10161.
87. Zhang X., Lee S.H., Min K.W., McEntee M.F., Jeong J., Li Q., Baek S.J. The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid. Cancer Prev. Res. (Phila.) 2013, 10.1158/1940-6207.CAPR-13-0220.
88. Nagelkerke A., Bussink J., van der Kogel A.J., Sweep F.C., Span P.N. The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. Radiother. Oncol. 2013, 10.1016/j.radonc.2013.06.037.
89. Fan C.F., Miao Y., Lin X.Y., Zhang D., Wang E.H. Expression of a phosphorylated form of ATF4 in lung and non-small cell lung cancer tissues. Tumour Biol. 2013, 10.1007/s13277-013-1104-5.
90. Wu X., Xin Z., Zhang W., Zheng S., Wu J., Chen K., Wang H., Zhu X., Li Z., Duan Z., Li H., Liu Y. A missense polymorphism in ATF6 gene is associated with susceptibility to hepatocellular carcinoma probably by altering ATF6 level. Int. J. Cancer 2013, 10.1002/ijc.28649.
91. Michallet A.S., Mondiere P., Taillardet M., Leverrier Y., Genestier L., Defrance T. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS One 2011, 6:e25820.
92. Teodoro T., Odisho T., Sidorova E., Volchuk A. Pancreatic beta-cells depend on basal expression of active ATF6alpha-p50 for cell survival even under nonstress conditions. Am. J. Physiol. Cell Physiol. 2012, 302:C992-C1003.
93. Senkal C.E., Ponnusamy S., Bielawski J., Hannun Y.A., Ogretmen B. Antiapoptotic roles of ceramide-synthase-6-generated C16-ceramide via selective regulation of the ATF6/CHOP arm of ER-stress-response pathways. FASEB J. 2010, 24:296-308.
94. Schewe D.M., Aguirre-Ghiso J.A. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10519-10524.
95. Morishima N., Nakanishi K., Nakano A. Activating transcription factor-6 (ATF6) mediates apoptosis with reduction of myeloid cell leukemia sequence 1 (Mcl-1) protein via induction of WW domain binding protein 1. J. Biol. Chem. 2011, 286:35227-35235.
96. Vilner B.J., John C.S., Bowen W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55:408-413.
97. Hayashi T., Su T.P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
98. Mori T., Hayashi T., Hayashi E., Su T.P. Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS One 2013, 8:e76941.
99. Spruce B.A., Campbell L.A., McTavish N., Cooper M.A., Appleyard M.V., O'Neill M., Howie J., Samson J., Watt S., Murray K., McLean D., Leslie N.R., Safrany S.T., Ferguson M.J., Peters J.A., Prescott A.R., Box G., Hayes A., Nutley B., Raynaud F., Downes C.P., Lambert J.J., Thompson A.M., Eccles S. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004, 64:4875-4886.
100. Kim F.J., Schrock J.M., Spino C.M., Marino J.C., Pasternak G.W. Inhibition of tumor cell growth by Sigma1 ligand mediated translational repression. Biochem. Biophys. Res. Commun. 2012, 426:177-182.
101. Chen D., Dou Q.P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11:459-470.
102. Jagannath S., Durie B.G., Wolf J., Camacho E., Irwin D., Lutzky J., McKinley M., Gabayan E., Mazumder A., Schenkein D., Crowley J. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 2005, 129:776-783.
103. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., Johri A.R., Jones P.E., Ivanova A., Van Deventer H.W., Gabriel D.A., Shea T.C., Mitchell B.S., Adams J., Esseltine D.L., Trehu E.G., Green M., Lehman M.J., Natoli S., Collins J.M., Lindley C.M., Dees E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
104. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
105. Kardosh A., Golden E.B., Pyrko P., Uddin J., Hofman F.M., Chen T.C., Louie S.G., Petasis N.A., Schonthal A.H. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res. 2008, 68:843-851.
106. Brem G.J., Mylonas I., Bruning A. Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression. Gynecol. Oncol. 2013, 128:383-390.
107. Polucci P., Magnaghi P., Angiolini M., Asa D., Avanzi N., Badari A., Bertrand J., Casale E., Cauteruccio S., Cirla A., Cozzi L., Galvani A., Jackson P.K., Liu Y., Magnuson S., Malgesini B., Nuvoloni S., Orrenius C., Sirtori F.R., Riceputi L., Rizzi S., Trucchi B., O'Brien T., Isacchi A., Donati D., D'Alessio R. Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships. J. Med. Chem. 2013, 56:437-450.
108. Wang Q., Li L., Ye Y. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J. Biol. Chem. 2008, 283:7445-7454.
109. Valle C.W., Min T., Bodas M., Mazur S., Begum S., Tang D., Vij N. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One 2011, 6:e29073.
110. Chou T.F., Brown S.J., Minond D., Nordin B.E., Li K., Jones A.C., Chase P., Porubsky P.R., Stoltz B.M., Schoenen F.J., Patricelli M.P., Hodder P., Rosen H., Deshaies R.J. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4834-4839.